Čájehuvvojit 1 - 3 oktiibuot 3 bohtosis ohcui A. E. van Leeuwen', ohcanáigi: 0,03s Aiddostahte ozu
  1. 1
    Personalized surveillance and aftercare for non-metastasized breast cancer: the NABOR study protocol of a multiple interrupted time series design

    Personalized surveillance and aftercare for non-metastasized breast cancer: the NABOR study protocol of a multiple interrupted time series design Dahkki A. Klaassen-Dekker, C. H. C. Drossaert, M. C. Van Maaren, A. E. Van Leeuwen-Stok, V. P. Retel, J. C. Korevaar, S. Siesling, on behalf of the NABOR project group

    Almmustuhtton 2023-11-01
    Viečča ollesdeavstta
    Artihkal
  2. 2
    Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade

    Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade Dahkki M. C. Liefaard, A. van der Voort, M. van Seijen, B. Thijssen, J. Sanders, S. Vonk, L. Mittempergher, R. Bhaskaran, L. de Munck, A. E. van Leeuwen-Stok, R. Salgado, H. M. Horlings, E. H. Lips, G. S. Sonke

    Almmustuhtton 2024-04-01
    Viečča ollesdeavstta
    Artihkal
  3. 3
    BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer

    BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer Dahkki M. C. Liefaard, A. van der Voort, M. S. van Ramshorst, J. Sanders, S. Vonk, H. M. Horlings, S. Siesling, L. de Munck, A. E. van Leeuwen, M. Kleijn, L. Mittempergher, M. M. Kuilman, A. M. Glas, J. Wesseling, E. H. Lips, G. S. Sonke

    Almmustuhtton 2023-06-01
    Viečča ollesdeavstta
    Artihkal

Ohcanreaiddut: